IDXX Stock Forecast: IDEXX Laboratories, Inc. Price Predictions for 2026-2027
The 14 Wall Street analysts covering IDEXX Laboratories, Inc. hold a median 12-month price target of $718 — +6.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 91 of 100 as at 21 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores IDEXX Laboratories, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (99): The business earns solid, repeatable profits on what it owns.
Accruals (41): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
IDXX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on IDXX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +6.1% from it.
Of the 20 most recent actions, 4 moved their price target up and 5 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 3 Nov 2026 | Morgan Stanley | Maintains | Overweight | $805 → $810 |
| 3 Nov 2026 | UBS | Maintains | Neutral | $627 → $700 |
| 27 Oct 2026 | UBS | Maintains | Neutral | $670 → $627 |
| 16 Oct 2026 | JP Morgan | Maintains | Overweight | $775 → $750 |
| 12 Oct 2026 | Keybanc | Initiates | Sector Weight | — |
| 11 Aug 2026 | Barclays | Maintains | Overweight | $800 → $710 |
| 5 Aug 2026 | Citigroup | Maintains | Neutral | $650 → $670 |
| 5 Aug 2026 | UBS | Maintains | Neutral | $620 → $670 |
| 27 July 2026 | UBS | Maintains | Neutral | $640 → $620 |
| 28 Apr 2026 | UBS | Maintains | Neutral | $730 → $640 |
| 15 Apr 2026 | Citigroup | Initiates | Neutral | — |
| 31 Mar 2026 | Stifel | Maintains | Buy | — |
| 9 Feb 2026 | Piper Sandler | Maintains | Neutral | — |
| 5 Feb 2026 | Barclays | Maintains | Overweight | — |
| 3 Feb 2026 | BTIG | Maintains | Buy | — |
| 3 Feb 2026 | UBS | Maintains | Neutral | — |
| 9 Dec 2025 | Barclays | Initiates | Overweight | — |
| 4 Nov 2025 | BTIG | Maintains | Buy | — |
| 4 Nov 2025 | JP Morgan | Maintains | Overweight | — |
| 4 Nov 2025 | Morgan Stanley | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for IDXX.
This page is one stock. Monday covers all of them.
IDXX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
IDXX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, IDEXX Laboratories, Inc. returned −1.9% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
IDXX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 45.6×
- Price / sales
- 11.4×
- Price / book
- 28.5×
- EV / EBITDA
- 32.3×
Cheaper than 18% of US stocks
Cheaper than 11% of US stocks
Cheaper than 2% of US stocks
Cheaper than 10% of US stocks
- Revenue growth (YoY)
- 9.9%
- Earnings growth (YoY)
- 15.5%
- Gross margin
- 64.0%
- Operating margin
- 32.5%
- Net margin
- 25.4%
Higher than 53% of US stocks
Higher than 55% of US stocks
Higher than 77% of US stocks
Higher than 89% of US stocks
Higher than 85% of US stocks
- Return on equity
- 68.9%
- Return on assets
- 26.7%
- Dividend yield
- —
Higher than 95% of US stocks
Higher than 99% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
IDEXX Laboratories, Inc. has a market value of $53.3B and an enterprise value of $54.1B.
Revenue in the twelve months to 30 June 2026: $4.6B. The latest quarter grew 9.7% year on year.
Net income over the same four quarters: $1.1B, a 25.0% net margin.
Diluted earnings per share, trailing twelve months: $14.22.
Free cash flow in the twelve months to 30 June 2026: $1.2B.
IDEXX Laboratories, Inc. spent $1.2B on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 45.6×; forward P/E: 40.0× — the forward figure prices analyst consensus estimates, not reported earnings.
IDEXX Laboratories, Inc. employs 11,000 people — $414K of revenue per employee.
Data provided by Twelve Data
IDXX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at IDXX’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own IDEXX Laboratories, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about IDXX
What is the IDXX stock price forecast for 2026-2027?
The 14 Wall Street analysts covering IDEXX Laboratories, Inc. have a median 12-month price target of $718, with estimates ranging from $470 to $810. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is IDXX stock a buy right now?
Of the 14 analysts covering IDEXX Laboratories, Inc., 9 rate it a Buy, 4 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks IDEXX Laboratories, Inc. 91 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank IDXX?
As at 21 Nov 2026, IDEXX Laboratories, Inc. ranks 91 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (99 of 100).
Will IDXX stock go up?
No one can know that. What the data says: the median 12-month target from 14 analysts implies +6.1% from the last close, and Ticker Nerd's factor model ranks IDEXX Laboratories, Inc. 91 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the IDXX stock forecast for 2030?
No analyst covering IDEXX Laboratories, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IDXX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $470 to $810 over the next 12 months.
How has IDXX stock performed over the past year?
IDEXX Laboratories, Inc. returned -1.9% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does IDEXX Laboratories, Inc. do?
IDEXX Laboratories, Inc. is a global diagnostics and software company focused on animal health, water quality, and agricultural testing. IDEXX Laboratories, Inc. develops and supplies in-clinic veterinary diagnostic instruments, consumable test kits, reference laboratory services, and practice management software that help veterinarians diagnose and monitor companion animals.
About IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc. is a global diagnostics and software company focused on animal health, water quality, and agricultural testing. IDEXX Laboratories, Inc. develops and supplies in-clinic veterinary diagnostic instruments, consumable test kits, reference laboratory services, and practice management software that help veterinarians diagnose and monitor companion animals. The company also provides testing solutions for livestock, poultry, and dairy producers, along with water microbiology products used to assess drinking water safety and quality. Its product portfolio is built around recurring consumables, laboratory workflows, and integrated software tools that support everyday clinical and operational decisions. IDEXX Laboratories, Inc. serves veterinary practices, animal health professionals, utilities, and food-production customers across global markets, making it an important provider of diagnostic infrastructure in the broader healthcare and environmental testing ecosystem.
CEO Mr. Michael G. Erickson Ph.D. · 11,000 employees · United States · https://www.idexx.com